biote Corp. (NASDAQ:BTMD) Major Shareholder Guines Llc Buys 106,000 Shares

biote Corp. (NASDAQ:BTMD) major shareholder Guines Llc acquired 106,000 shares of the business’s stock in a transaction dated Monday, March 31st. The stock was acquired at an average price of $3.32 per share, with a total value of $351,920.00. Following the completion of the transaction, the insider now directly owns 4,033,547 shares of the company’s stock, valued at approximately $13,391,376.04. This represents a 2.70 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Guines Llc also recently made the following trade(s):

• On Monday, March 17th, Guines Llc purchased 100 shares of biote stock. The stock was bought at an average cost of $3.74 per share, for a total transaction of $374.00.
• On Thursday, March 13th, Guines Llc acquired 750,000 shares of biote stock. The shares were bought at an average price of $3.22 per share, with a total value of $2,415,000.00.

biote Trading Down 2.1 %

NASDAQ:BTMD opened at $3.29 on Friday. The stock has a 50 day moving average of $4.35 and a two-hundred day moving average of $5.31. biote Corp. has a 12 month low of $3.04 and a 12 month high of $8.44. The firm has a market cap of $180.00 million, a P/E ratio of 12.65 and a beta of 1.07.

Institutional Trading of biote

Institutional investors have recently made changes to their positions in the company. Barclays PLC lifted its holdings in biote by 52.3% in the 3rd quarter. Barclays PLC now owns 77,196 shares of the company’s stock valued at $432,000 after purchasing an additional 26,510 shares in the last quarter. Kanen Wealth Management LLC acquired a new stake in shares of biote in the fourth quarter valued at about $1,791,000. State Street Corp lifted its stake in shares of biote by 13.7% in the third quarter. State Street Corp now owns 475,491 shares of the company’s stock worth $2,653,000 after buying an additional 57,290 shares in the last quarter. Jane Street Group LLC boosted its position in biote by 24.7% during the third quarter. Jane Street Group LLC now owns 16,873 shares of the company’s stock worth $94,000 after acquiring an additional 3,342 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in biote during the fourth quarter worth about $76,000. 21.68% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Craig Hallum dropped their target price on shares of biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.